Advertisement

Octreotide Injection

[21 November 2016]

Products Affected - Description

Octreotide Acetate injection, Fresenius Kabi
50 mcg/mL, 1 mL vial, 10 count (NDC 63323-0365-01)
 
Octreotide Acetate injection, Mylan Institutional
50 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0239-01)
 
Octreotide Acetate injection, Sagent
50 mcg/mL, 1 mL vial, 10 count (NDC 25021-0451-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 25021-0454-05)
500 mcg/mL, 1 mL vial, 10 count (NDC 25021-0453-01)
 
Octreotide Acetate injection, Sun Pharma
50 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0348-44)
100 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0349-44)
200 mcg/mL, 5 mL vial, 1 count (NDC 62756-0350-40)
500 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0351-44)
1000 mcg/mL, 5 mL vial, 1 count (NDC 62756-0352-40)

Reason for the Shortage

  • Fresenius Kabi did not provide a reason for the shortage.
  • Sagent has octreotide on shortage due to manufacturing delays.
  • Teva is relaunching several presentations this year.
  • Sun Pharma will not provide availability information at this time.

Available Products

Sandostatin injection, Novartis
50 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0180-01)
100 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0181-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 00078-0183-25)
500 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0182-01)
1000 mcg/mL, 5 mL vial, 1 count (NDC 00078-0184-25)
 
Octreotide Acetate injection, Fresenius Kabi
100 mcg/mL, 1 mL vial, 10 count (NDC 63323-0376-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 63323-0378-05)
500 mcg/mL, 1 mL vial, 10 count (NDC 63323-0377-01)
1000 mcg/mL, 5 mL vial, 1 count (NDC 63323-0379-05)
 
Octreotide Acetate injection, Mylan Institutional
100 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0245-01)
500 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0246-01)
 
Octreotide Acetate injection, Sagent
100 mcg/mL, 1 mL vial, 10 count (NDC 25021-0452-01)
1000 mcg/mL, 5 mL vial, 1 count (NDC 25021-0455-05)
 
Octreotide Acetate injection, Teva
50 mcg/mL, 1 mL vial, 25 count (NDC 00703-3301-04)
100 mcg/mL, 1 mL vial, 25 count (NDC 00703-3311-04)
200 mcg/mL, 5 mL vial, 1 count (NDC 00703-3333-01)
500 mcg/mL, 1 mL vial, 25 count (NDC 00703-3321-04)
1000 mcg/mL, 5 mL vial, 1 count (NDC 00703-3343-01)

Estimated Resupply Dates

  • Fresenius Kabi has octreotide 50 mcg/mL 1 mL vials on back order and the company estimates a release date of 1st quarter 2017.
  • Mylan Institutional has octreotide 50 mcg/mL 1 mL syringes on back order and the company estimates a release date of late-November 2016.
  • Sagent has octreotide 50 mcg/mL 1 mL vials and 200 mcg/mL 5 mL vials on back order and the company estimates a release date of November 2016. The 500 mcg/mL 1 mL vials are on allocation.

Related Shortages

Updated

November 21 and 10, October 5, August 25, 18 and 5, July 14, June 28, May 27, 20 and 17, April 14 and 13, March 16, 2016, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing